Brief: Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of MG3

Sanofi SA

28/05/2026 06:07

       May 28 (Reuters) - Sanofi SA  SASY.PA :
    * FDA GRANTS PRIORITY REVIEW TO VENGLUSTAT NDA
    * VENGLUSTAT RECEIVED BREAKTHROUGH, FAST TRACK, AND ORPHAN
DRUG DESIGNATIONS FOR MG3
    * TO PURSUE ADDITIONAL GLOBAL REGULATORY FILINGS FOR
VENGLUSTAT IN 2026
    * IF APPROVED, VENGLUSTAT WOULD BECOME THE FIRST TREATMENT
AVAILABLE IN THE UNITED STATES FOR THE PROGRESSIVE NEUROLOGICAL
SYMPTOMS ASSOCIATED WITH MG3

    Source text: [ID: nGNXb4vSt6]
    Further company coverage:  SASY.PA 

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))